Abstract
In India, thousands of COVID-19 patients are suffering from mucormycosis, a deadly fungal infection. Mucormycosis is an infection caused by a group of filamentous molds belonging to the order Mucorales and class Zygomycetes. Typically, mucormycosis is called black fungus disease. The infection primarily affects diabetics and immunocompromised patients. Infections caused by this fungal infection can be divided into four types: rhino-orbito-cerebral, cutaneous, disseminated, pulmonary, and gastrointestinal types. The mortality rate is higher even when aggressive treatment has been administered once it is detected or diagnosed. A multimodal approach to mucormycosis management involves reversing or discontinuing the predisposing factors, administering active antifungal agents at optimal doses, removing all infected tissues, and employing adjuvant therapy. The purpose of this review is to provide brief details related to the etiopathogenesis, fatality, diagnosis, and treatment of mucormycosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Datta Meghe Institute of Medical Sciences University
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
